Ribupatide
An investigational once-weekly dual GLP-1/GIP receptor agonist from Jiangsu Hengrui, with ex-Greater China rights held by Kailera Therapeutics. Phase 3 in China produced up to 19.2% weight loss at 48 weeks; a global Phase 3 (KaiNETIC) began enrolling in January 2026.
What is Ribupatide?
Ribupatide is an investigational once-weekly dual GLP-1/GIP receptor agonist developed by Jiangsu Hengrui Pharmaceuticals (Shanghai), with ex-Greater China rights licensed to Kailera Therapeutics. It shares its receptor profile with tirzepatide but is a distinct molecule designed around a balanced dual-agonist pharmacology Kailera has described preclinically as more potent and longer-acting than Eli Lilly's tirzepatide. Hengrui's Phase 3 trial in China (HRS9531-301, n=567) reported 11.2%, 17.4%, and 19.2% mean weight loss at 2, 4, and 6 mg weekly over 48 weeks, and Hengrui's NMPA marketing authorization application in China has been accepted. Kailera's global KaiNETIC Phase 3 program — three placebo-controlled trials testing weekly doses up to 10 mg over 76 weeks, with an active semaglutide 2.4 mg comparator in one arm — began randomizing participants in January 2026, with results anticipated in 2028. A separate oral formulation (KAI-9531-T / HRS9531-T) completed Phase 2 in early 2026 and produced up to 12.1% weight loss at 26 weeks.
What Ribupatide Is Investigated For
Ribupatide is being developed for chronic weight management and — like tirzepatide — is expected to extend into type 2 diabetes and related cardiometabolic indications, though the published evidence so far is squarely obesity-focused. The strongest human data comes from Hengrui's China Phase 3 trial (HRS9531-301) in 567 adults with obesity or overweight: at 48 weeks, mean weight loss on the hypothetical estimand was 11.2% (2 mg), 17.4% (4 mg), and 19.2% (6 mg) versus 1.4% for placebo, with 88.0% of treated participants achieving ≥5% weight loss and 44.4% achieving ≥20%. A Phase 2 cohort at a higher 8 mg dose reported 23.6% weight loss at 36 weeks after only 12 weeks at the maintenance dose, with no observed plateau — one of the reasons Kailera's KaiNETIC global program extends out to 10 mg weekly and 76 weeks of dosing. An oral once-daily formulation produced 6.9%, 12.1%, and 12.1% mean weight loss at 10, 25, and 50 mg at 26 weeks in a 166-participant Phase 2 trial in China. The honest caveats: ribupatide is not FDA-approved anywhere outside of China's pending NMPA review, every published Phase 2/3 result enrolled Chinese participants (generalizability to other populations is the stated rationale for KaiNETIC), long-term safety beyond roughly a year is uncharacterized, and cross-trial comparisons to tirzepatide or semaglutide should be interpreted with the usual methodological caution until KaiNETIC-3's active-comparator arm reads out.
History & Discovery
Ribupatide (originator code HRS9531; Kailera code KAI-9531) was discovered and developed by Jiangsu Hengrui Pharmaceuticals, one of China's largest domestic drug developers, as part of a strategic push into innovator incretin biology alongside a long-established generics business. The molecule was designed as a balanced dual agonist of the GLP-1 and GIP receptors — the same receptor profile as Eli Lilly's tirzepatide — but engineered from a different peptide scaffold with the stated goal of higher potency and longer duration of action. Hengrui first reported Phase 2 weight-loss data in Chinese adults with obesity, including a distinctive 8 mg weekly cohort that produced 23.6% mean weight loss at 36 weeks with no observed plateau, a result that drew international attention and motivated dosing out to 10 mg weekly in later programs. In 2024, Hengrui licensed ex-Greater China rights to ribupatide to Kailera Therapeutics — a US-based obesity-focused company led by CEO Ron Renaud and backed by specialist biotech investors. Kailera went public in April 2026, raising $625 million in an IPO priced at the top of the expected range, with ribupatide as the lead asset. The pivotal Hengrui Phase 3 trial in China (HRS9531-301, n=567) reported topline results in July 2025 showing up to 19.2% mean weight loss at the 6 mg dose over 48 weeks; Hengrui subsequently submitted a marketing authorization application to China's National Medical Products Administration for chronic weight management, and the submission has been accepted for review. Kailera's global KaiNETIC Phase 3 program (three trials evaluating weekly doses up to 10 mg over 76 weeks, including a head-to-head semaglutide 2.4 mg open-label arm in KaiNETIC-3) began randomizing participants in January 2026, with readouts expected in 2028. A parallel oral formulation (HRS9531-T / KAI-9531-T) completed a 166-participant Phase 2 trial in China in early 2026 and is slated to enter global mid-stage studies in 2026 with 2027 readouts.
How It Works
Ribupatide activates two gut-hormone receptors at once — GLP-1 (which reduces appetite and improves blood sugar) and GIP (which complements GLP-1 signaling and may help with fat distribution and tolerability). The combination produces appetite suppression, delayed gastric emptying, and improved glucose control, with a once-weekly subcutaneous injection.
Ribupatide is a long-acting peptide dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). GLP-1R activation stimulates glucose-dependent insulin secretion from pancreatic β-cells, suppresses glucagon release, delays gastric emptying, and engages hypothalamic and brainstem circuits to suppress appetite. GIPR activation enhances insulin secretion under hyperglycemic conditions, may improve adipose tissue buffering of postprandial lipids, and is believed to contribute centrally to satiety through distinct neural pathways from GLP-1, while also mitigating some of the GI-tolerability issues associated with pure GLP-1 agonism. Ribupatide's developer has described preclinical data suggesting a more potent and longer-acting profile than tirzepatide at the receptor level; the peptide is formulated for once-weekly subcutaneous administration. A separate oral formulation (ribupatide tablets; HRS9531-T / KAI-9531-T) uses permeation-enhancing technology analogous to oral semaglutide to achieve sufficient systemic exposure from daily oral dosing.
Evidence Snapshot
Human Clinical Evidence
Moderate. Hengrui's Phase 3 HRS9531-301 in 567 Chinese participants showed 11.2/17.4/19.2% mean weight loss at 2/4/6 mg weekly over 48 weeks. A Phase 2 cohort at 8 mg reported 23.6% weight loss at 36 weeks. Oral formulation Phase 2 (n=166) showed 6.9/12.1/12.1% at 10/25/50 mg over 26 weeks. Global Phase 3 KaiNETIC program enrolling as of January 2026; readouts anticipated 2028. Not FDA-approved.
Animal / Preclinical
Supportive. Kailera has publicly described preclinical characterization showing higher potency and longer-lasting effects than tirzepatide, though peer-reviewed primary preclinical publications are limited.
Mechanistic Rationale
Strong. Dual GLP-1/GIP agonism is a well-validated mechanism by tirzepatide's Phase 3 and post-marketing evidence.
Research Gaps & Open Questions
What the current literature has not yet settled about Ribupatide:
- 01Global Phase 3 efficacy and safety — KaiNETIC-1, -2, and -3 are still enrolling, with readouts anticipated in 2028; the published evidence base outside China is currently limited to Phase 2 extensions and the oral-formulation Phase 2.
- 02Cardiovascular outcomes — no dedicated cardiovascular outcomes trial has been completed or reported for ribupatide, leaving macrovascular risk reduction unresolved.
- 03Head-to-head vs tirzepatide — KaiNETIC-3 includes a semaglutide 2.4 mg open-label comparator but no tirzepatide arm; relative positioning against the other dual GLP-1/GIP agonist will rely on indirect comparison.
- 04Long-term safety beyond 76 weeks — all reported and planned trials end at or before that duration; chronic multi-year safety data is not yet available.
- 05Weight-regain kinetics after discontinuation — no published withdrawal-arm data comparable to SURMOUNT-4 or STEP-1 extension.
- 06Oral formulation global development — the oral Phase 2 read out in China in early 2026; global efficacy, safety, and bioavailability profile in non-Chinese populations is not yet characterized.
- 07Body composition effects — the balance of fat versus lean mass loss at higher doses (8–10 mg) across the full KaiNETIC dose range has not been reported in detail.
- 08Non-obesity indications — any expansion into type 2 diabetes, MASH/MASLD, cardiovascular disease, or obstructive sleep apnea is speculative pending dedicated trial programs.
Forms & Administration
Once-weekly subcutaneous injection for the injectable formulation; once-daily oral tablet for the separate oral formulation under development. Ribupatide is investigational and available only through enrollment in sponsor-run clinical trials. All injectable peptides should only be administered under the guidance of a qualified healthcare provider.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Ribupatide is investigational; doses below reflect trial protocols, not consumer or prescribing guidance. Hengrui's Phase 3 HRS9531-301 evaluated 2, 4, and 6 mg weekly subcutaneous maintenance doses following gradual titration. An earlier Phase 2 cohort extended to 8 mg weekly. Kailera's KaiNETIC-1 and KaiNETIC-2 trials randomize to 4, 6, 8, or 10 mg weekly or placebo; KaiNETIC-3 randomizes to 8 or 10 mg weekly, placebo, or open-label semaglutide 2.4 mg. The separate oral formulation has been tested at 10, 25, and 50 mg once daily (HRS9531-T-201 Phase 2).
Frequency
Once weekly subcutaneous injection for the injectable formulation. Once daily oral for the separate tablet formulation. Trial protocols permit SC injection on any day of the week at approximately the same day each week.
Cycle Length
Ribupatide has not been approved or released for clinical use outside of China's pending NMPA review, so 'protocol length' outside trials is not defined. The China Phase 3 trial ran 48 weeks; the KaiNETIC global Phase 3 program runs 76 weeks with up to 24 weeks of dose titration and at least 52 weeks of maintenance dosing. If ribupatide reaches approval for obesity, the anticipated usage pattern — based on mechanism and on the tirzepatide/semaglutide precedent — will be indefinite chronic use, with substantial weight regain expected after discontinuation. No published withdrawal-arm data is yet available.
Protocol Notes
Ribupatide is not legally available outside clinical trials in the United States or any other jurisdiction as of early 2026. Trial participants receive investigational drug product from the sponsor. Compounded ribupatide has begun appearing on grey-market and research-chemical websites; because ribupatide is an unapproved investigational drug and is not on any validated bulk drug substance list for compounding, such products are not operating within an approved framework and carry unresolved identity, purity, potency, and regulatory concerns. GI tolerability in Phase 2 and Phase 3 trials has been broadly consistent with the GLP-1 class, with dose-dependent nausea, vomiting, and diarrhea concentrating at titration steps; trial reports to date indicate low discontinuation rates for GI adverse events and no observed weight-loss plateau through 36–48 weeks of dosing at 6–8 mg.
Ribupatide is not FDA-approved. Outside of enrollment in Hengrui- or Kailera-sponsored clinical trials, there is no legitimate supply of ribupatide in the United States; the description above reflects published trial design, not prescribing guidance.
Timeline of Effects
Onset
In Phase 2 and Phase 3 trials, weight-loss separation from placebo was visible within the first weeks of dosing and was clearly established by week 12. Appetite suppression is reported within the first 1–2 weeks of starting ribupatide, consistent with the GLP-1 and GIP components of the mechanism. Dose titration over 20–24 weeks tempers the early tolerability burden while building toward maintenance dose exposure.
Peak Effect
At 48 weeks in HRS9531-301, participants at 6 mg weekly lost 19.2% of body weight on the hypothetical estimand with no clearly established plateau, suggesting continued weight loss with longer exposure. A separate Phase 2 cohort at 8 mg reported 23.6% weight loss at 36 weeks after only 12 weeks of maintenance dosing, also without an observed plateau. The KaiNETIC global Phase 3 program's 76-week follow-up at doses up to 10 mg weekly is expected to characterize the peak-effect window and any plateau point more completely.
After Discontinuation
No published withdrawal or extension-phase data exist for ribupatide as of early 2026. Based on mechanistic parallels to semaglutide and tirzepatide — both of which show roughly two-thirds weight regain within a year of discontinuation — the working expectation is that ribupatide will behave similarly, with weight regain proportional to the weight lost. This assumption awaits dedicated withdrawal-arm data from the KaiNETIC program or post-approval studies.
Common Questions
Who Ribupatide Is NOT For
- •Personal or family history of medullary thyroid carcinoma (MTC) — the incretin-class boxed warning is expected to apply to ribupatide based on shared rodent C-cell tumor findings across GLP-1 and GIP/GLP-1 agonists.
- •Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — same mechanistic concern as MTC.
- •Active pancreatitis or history of recurrent pancreatitis — the GLP-1 class pancreatitis signal applies; trial protocols have excluded participants with prior pancreatitis.
- •Pregnancy — investigational drug with no human reproductive safety data; trial protocols exclude pregnant and breastfeeding participants.
- •Breastfeeding — no data on transfer into milk or infant effects.
- •Severe gastroparesis or significant gastrointestinal motility disorders — delayed gastric emptying from the GLP-1 component can worsen symptoms.
- •Pediatric use (under 18) — no pediatric studies; the current development program is adult-only.
- •Type 1 diabetes — the dual agonist has not been characterized in T1D populations; trial protocols have excluded T1D participants.
Drug & Supplement Interactions
No dedicated drug-interaction studies have been published for ribupatide as of early 2026, so the following is inferred from the broader GLP-1 and dual GLP-1/GIP receptor agonist class and should not be treated as definitive prescribing guidance. Combination with insulin or insulin secretagogues (sulfonylureas, meglitinides) in patients with diabetes raises hypoglycemia risk and typically requires downward dose adjustment of the background hypoglycemic agent. Ribupatide's delayed gastric emptying may alter the absorption of orally administered medications, particularly those with narrow therapeutic indices or time-sensitive kinetics — warfarin (INR monitoring), levothyroxine (TSH monitoring), and oral hormonal contraceptives are the most clinically relevant examples in the GLP-1 class. Modest dose-dependent heart-rate elevation has been observed across incretin therapies and may compound with beta-agonists, thyroid replacement, stimulants, or sympathomimetics; ribupatide's specific cardiovascular pharmacodynamic profile will be further characterized in the KaiNETIC program and any cardiovascular outcomes trials that follow. Because ribupatide is not yet approved, no prescribing-information interaction table exists; the discussion here is mechanism-inferred and should be treated as preliminary.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved; outside of clinical trials there is no legitimate supply
- • Long-term safety beyond approximately one year is uncharacterized
- • Pivotal efficacy data to date enrolled exclusively Chinese participants; global generalization is pending
- • GI tolerability is dose-dependent and concentrates at titration steps
What We Don't Know
Cardiovascular outcomes, long-term safety beyond 48–76 weeks, head-to-head performance against tirzepatide, and sustained effect after discontinuation are all still being characterized. The oral formulation's global development program is earlier-stage.
Legal Status
United States
Ribupatide is not FDA-approved for any indication. It is an investigational drug under Kailera Therapeutics' US development program, available exclusively through enrollment in sponsor-run clinical trials (the KaiNETIC program). There is no legal compounding pathway for ribupatide in the United States — compounding under 503A requires either an FDA-approved reference product (which does not exist) or a validated bulk drug substance list entry (which does not apply here). Research-chemical suppliers advertising ribupatide are not operating within an approved clinical or compounding framework.
International
Hengrui has submitted a marketing authorization application to China's NMPA for chronic weight management based on HRS9531-301, and the submission has been accepted for review; approval in China has not been granted as of April 2026. No other major regulator — EMA, UK MHRA, Health Canada, Australia's TGA — has authorized ribupatide. KaiNETIC Phase 3 has sites in multiple jurisdictions, so trial access varies by country. Personal-use importation of research-chemical ribupatide is prohibited or restricted in most jurisdictions.
Sports & Competition
Ribupatide is not currently listed by name on the WADA Prohibited List, but WADA's S0 category prohibits any substance 'not currently approved by any governmental regulatory health authority for human therapeutic use' — a description that encompasses ribupatide outside of any eventual China approval. Athletes subject to the WADA code should treat ribupatide as prohibited in and out of competition.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Ribupatide is just a Chinese copy of tirzepatide.
Reality
Ribupatide and tirzepatide share a receptor profile — both are dual GLP-1/GIP agonists — but they are distinct peptide molecules developed independently by different companies. Ribupatide's developer has characterized it preclinically as more potent and longer-acting than tirzepatide, though no head-to-head human trial has been completed to validate those claims. Framing ribupatide as a 'copy' understates both the design work and the independent Phase 3 evidence base the program has generated.
Myth
Because ribupatide produces more weight loss than tirzepatide in cross-trial comparisons, it must be better.
Reality
Cross-trial comparisons between different dual GLP-1/GIP agonists tested in different populations with different protocols are methodologically weak. Ribupatide's reported weight-loss figures at 6 and 8 mg look favorable on their face but enrolled exclusively Chinese participants with a lower baseline body weight than SURMOUNT trial participants, which can inflate percentage-based weight-loss figures. Until KaiNETIC reads out in diverse global populations, and ideally until a head-to-head trial against tirzepatide is completed, relative ranking cannot be confidently claimed.
Myth
Ribupatide is already available from reputable research-chemical vendors.
Reality
Ribupatide is an unapproved investigational drug. Outside of enrollment in Hengrui- or Kailera-sponsored clinical trials, there is no FDA-sanctioned clinical or compounding pathway for obtaining ribupatide in the United States, and no other major jurisdiction has approved it either. Research-chemical suppliers marketing ribupatide are not operating within any approved framework; identity, purity, potency, and sterility cannot be verified.
Myth
The oral formulation of ribupatide matches the injectable on weight loss.
Reality
At 26 weeks, oral ribupatide produced roughly 12% weight loss at 25 and 50 mg daily — a meaningful result for an oral peptide, but short of the 17–19% seen with the injectable at 48 weeks. The oral formulation also requires larger doses and more frequent (daily) administration. The two formulations should be thought of as separate products with different patient fits rather than as interchangeable forms of the same drug.
Myth
Ribupatide is approved in China.
Reality
Hengrui has submitted a marketing authorization application to China's NMPA, and that submission has been accepted for review, but approval has not been granted as of April 2026. Acceptance of the filing is a procedural milestone, not a regulatory endorsement of efficacy or safety.
Published Research
9 studiesKailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)
January 2026 announcement describing the three-trial KaiNETIC global Phase 3 program — KaiNETIC-1 and -2 randomize to 4, 6, 8, or 10 mg weekly SC ribupatide or placebo; KaiNETIC-3 randomizes to 8 or 10 mg, placebo, or open-label semaglutide 2.4 mg, with 76-week duration and up to 24-week titration.
Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
July 2025 topline readout of HRS9531-301 (n=567, 48 weeks) in Chinese participants with obesity or overweight. Mean weight loss on the hypothetical estimand: 11.2% (2 mg), 17.4% (4 mg), 19.2% (6 mg) vs 1.4% placebo. Up to 88.0% achieved ≥5% and 44.4% achieved ≥20% weight loss; NMPA marketing authorization application accepted.
Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
November 2025 supplementary dataset from HRS9531-301, including cardiometabolic and responder-analysis readouts presented at ObesityWeek 2025.
Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide
February 2026 Phase 2 readout (HRS9531-T-201) of once-daily oral ribupatide (10, 25, 50 mg) in 166 Chinese adults with obesity without type 2 diabetes. Mean weight loss at 26 weeks: 6.9%, 12.1%, 12.1% vs 2.3% placebo (efficacy estimand). Vomiting ≤11.4%; no treatment discontinuations or dose reductions for GI events.
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531
Phase 2 readout at 8 mg weekly SC: 23.6% mean weight loss from baseline at 36 weeks (after 12 weeks at the 8 mg maintenance dose) versus 1.8% placebo, with no observed plateau — supporting the 8 mg and 10 mg arms in the KaiNETIC global Phase 3 program.
Kailera raises $625M in IPO, betting its obesity drugs can outperform Zepbound
Biopharma Dive coverage of Kailera's April 2026 IPO. Summarizes the ribupatide commercial thesis — Phase 3 global studies reading out in 2028, Phase 2b higher-dose studies in 2027, and an oral formulation entering global mid-stage trials in 2026 — and Kailera's positioning of the asset against Eli Lilly's Zepbound.
Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek 2025
Ribupatide, An Oral Dual GLP-1/GIP, Achieves Weight Loss in Phase 2 Obesity Trial
Kailera | GLP-1 Therapy for Obesity | Ribupatide
Quick Facts
- Class
- Dual GLP-1/GIP Receptor Agonist
- Evidence
- Emerging
- Safety
- Limited Data
- Updated
- Apr 2026
- Citations
- 9PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.